Suraksha Diagnostic appoints Shreya Arora as company secretary

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Shreya Arora appointed as Company Secretary and Compliance Officer effective October 14, 2026
  • Appointment approved by the Board based on Nomination and Remuneration Committee recommendation
  • Arora brings over 12 years of experience in corporate secretarial functions and legal affairs
  • Previous role included serving as Company Secretary and Legal Head at Kutchina Home Makers Private Limited
powered bylight_fuzz_icon
53525964

*this image is generated using AI for illustrative purposes only.

Suraksha Diagnostic Ltd appointed Shreya Arora as Company Secretary and Compliance Officer effective October 14, 2026. The appointment was approved by the Board of Directors based on the recommendation of the Nomination and Remuneration Committee.

The decision was taken during a board meeting held on Wednesday, October 14, 2026. The meeting commenced at 4:30 pm and concluded at 4:40 pm. This intimation was filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Profile of the new appointee

Arora is an Associate Member of the Institute of Company Secretaries of India (ICSI). She holds a Bachelor of Commerce (B.Com. Hons.) degree from the University of Calcutta and a Bachelor of Laws (LL.B. Hons.) degree from Bankura University.

Her professional background includes over 12 years of experience in corporate secretarial functions, legal affairs, and regulatory compliance. Prior to joining Suraksha Diagnostic, she served as Company Secretary and Legal Head at Kutchina Home Makers Private Limited. Her expertise spans corporate governance, statutory compliance, and legal matters.

Board meeting details

The board meeting addressed two primary items:

  1. Appointment of the Company Secretary and Compliance Officer.
  2. Comments on the delay in filing the shareholding pattern with the National Stock Exchange of India Limited.

The company signed the disclosure with Ritu Mittal, Joint Managing Director and CEO.

Historical Stock Returns for Suraksha Diagnostic

1 Day5 Days1 Month6 Months1 Year5 Years
+1.24%-4.13%-1.68%+15.36%+11.45%-23.71%

How might the appointment of Shreya Arora address the specific compliance gaps highlighted by the recent delay in filing the shareholding pattern with the NSE?

Will Suraksha Diagnostic's enhanced compliance framework under Arora's leadership influence its standing with SEBI regarding future regulatory disclosures?

What strategic shifts in corporate governance can investors expect from Suraksha Diagnostic given Arora's extensive background in legal affairs and statutory compliance?

Suraksha Diagnostic AGM: All resolutions passed, director re-appointment sees 10% dissent

scanx
Reviewed by
Naman SScanX News Team
Key Highlights
  • Shareholders approved all five resolutions at the 21st AGM held on September 22, 2026
  • Final dividend of ₹0.50 per equity share declared for FY26
  • Re-appointment of director Satish Kumar Verma passed with 90.08% support, seeing 9.92% dissent
  • Institutional investors cast 22.70% of their votes against the director's re-appointment
  • Total votes polled across resolutions ranged between 36.69 million and 42.34 million
powered bylight_fuzz_icon
51631152

*this image is generated using AI for illustrative purposes only.

Suraksha Diagnostic Limited shareholders approved all five resolutions at the 21st Annual General Meeting (AGM) held on September 22, 2026. The meeting confirmed the adoption of FY26 financial statements and the declaration of a final dividend of ₹0.50 per equity share.

The virtual meeting, conducted via video conferencing from 11:30 am to 12:17 pm IST, saw all ordinary and special business items passed by requisite majority. Dr. Somnath Chatterjee chaired the session, while Ritu Mittal, Joint Managing Director and CEO, briefed members on company affairs and growth during FY26.

Key Resolutions Passed

The following agenda items were adopted by the shareholders:

Item Description Resolution Type Result
1 Adoption of audited standalone financial statements for FY26 Ordinary Passed
2 Adoption of audited consolidated financial statements for FY26 Ordinary Passed
3 Declaration of final dividend of ₹0.50 per equity share Ordinary Passed
4 Re-appointment of Satish Kumar Verma as Non-Executive Non-Independent Director Ordinary Passed
5 Ratification of remuneration for Cost Auditor M/s. S. Chhaparia & Associates for FY27 Ordinary Passed

Meeting Proceedings and Governance

The CFO highlighted the company's financial performance and growth trajectory for the fiscal year ended March 31, 2026. All directors attended the meeting except Satish Kumar Verma, who was absent due to personal reasons. Sandhya Malhotra, Practicing Company Secretary at M/s Manish Ghia and Associates, served as the scrutinizer to oversee remote e-voting and voting during the meeting.

Statutory Registers and relevant documents were accessible electronically throughout the session. The recording of the meeting is available on the company's website. Voting results will be submitted to stock exchanges in compliance with SEBI Listing Regulations.

Voting Results Breakdown

The company disclosed detailed voting results pursuant to Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. A total of 62,150 shareholders were on record as of September 15, 2026. The following table summarizes the vote distribution for each resolution:

Resolution Votes In Favour (%) Votes Against (%) Total Votes Polled
1. Standalone Financials 99.9989% 0.0011% 42,338,135
2. Consolidated Financials 99.9990% 0.0010% 42,338,135
3. Final Dividend 99.9992% 0.0008% 42,338,135
4. Director Re-appointment 90.0827% 9.9173% 36,694,164
5. Cost Auditor Remuneration 99.9988% 0.0012% 42,338,135

What the Numbers Show

While four of the five resolutions received near-unanimous support (>99.99%), Resolution 4 regarding the re-appointment of Mr. Satish Kumar Verma saw significant dissent. Approximately 9.92% of the votes polled were cast against this resolution. This dissent was driven primarily by Public-Institutions, where 22.70% of the votes polled were against the re-appointment, compared to just 0.03% among Public-Non Institutions. Promoters voted in favour but abstained from voting on this specific item relative to their full holding, casting 18.49 million votes out of their 24.14 million holdings.

Historical Stock Returns for Suraksha Diagnostic

1 Day5 Days1 Month6 Months1 Year5 Years
+1.24%-4.13%-1.68%+15.36%+11.45%-23.71%

How will the 9.92% dissent against Satish Kumar Verma's re-appointment, particularly from institutional investors, impact the board's governance strategy and potential director reshuffles in FY27?

What specific growth initiatives did CEO Ritu Mittal highlight during the AGM that are expected to drive Suraksha Diagnostic's performance in the upcoming fiscal year?

Given the promoter abstention on the director re-appointment resolution, what underlying concerns or strategic misalignments might exist between the promoter group and public institutions?

More News on Suraksha Diagnostic

1 Year Returns:+11.45%